SAR 446523
Alternative Names: SAR-446523Latest Information Update: 16 Oct 2024
At a glance
- Originator Sanofi-Aventis GmbH
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Antibody-dependent cell cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Multiple myeloma
Most Recent Events
- 08 Oct 2024 Sanofi plans a phase I trial for Multiple myeloma (Second-line therapy or greater) (SC) (NCT06630806)
- 02 Jul 2024 Preclinical trials in Multiple myeloma in France (unspecified route)
- 05 Apr 2024 Pharmacodynamics and safety data from preclinical studies in Multiple myeloma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)